Perspective, Therapeutics (CATX) announced that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other Friday’s ...

K reports of America’s largest pharmaceutical companies show that they continue to avoid paying much, if any, U.S. corporate income tax.

Two of the most influential voices in strategic communication ? Baron Evans of Sealand and Paul Holmes, will take center stage at the Davos Communications Summit & Awards 2025 on April 10 at the Davos ...

Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...

The most recent trading session ended with Bristol Myers Squibb (BMY) standing at $60.28, reflecting a +0.79% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily ...

Bristol-Myers Squibb (BMY) is ranked 5th among the best pharma stocks to buy according to hedge funds. The company boasts a ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

This was the stock's second consecutive day of losses.

Emergen Research Logo The increasing prevalence of liver diseases worldwide is a major growth driver in the liver disease therapeutics mark ...

Bristol Myers Squibb’s dividend yield crossed the 4% mark, making it an attractive option for income-focused investors. The ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...